Aditxt Inc (ADTX)

Apr 2, 2025, 8:15 AM EDT - 21 hours ago

Appili President and CEO, Don Cilla Will Join Aditxt Co-founder and CEO, Amro Albanna, at the Aditxt Weekly Update on April 4, 2025

Mar 28, 2025, 8:15 AM EDT - 5 days ago

Upcoming Aditxt Weekly Update to Highlight Pearsanta's Acquisition of the Adductomics-Based CaSe Platform and its Potential for Early Cancer Detection

Mar 24, 2025, 8:30 AM EDT - 9 days ago

Evofem Reports Fourth Consecutive Year of Net Sales Growth

WINT

Mar 24, 2025, 8:15 AM EDT - 9 days ago

Aditxt Subsidiary Pearsanta Completes the Acquisition of Proprietary Adductomics Technology to Develop and Advance the Platform Toward Clinical and Commercial Applications for Monitoring Early Signs of Increased Cancer Risk

Mar 17, 2025, 8:15 AM EDT - 16 days ago

Aditxt Provides Business Status Overview and Announces Launch of Aditxt Weekly Update Starting Friday, March 21, 2025

Mar 12, 2025, 4:15 PM EDT - 21 days ago

Aditxt, Inc. (NASDAQ: ADTX) Announces 1-for-250 Reverse Stock Split Effective at the Open of Trading on March 17, 2025

Mar 6, 2025, 8:15 AM EST - 27 days ago

Aditxt Subsidiary Adimune to Ship Drug Substances for Final Drug Product Formulation of ADI-100 Ahead of Planned Clinical Trials in Type 1 Diabetes and Psoriasis in Germany, and Stiff Person Syndrome at the Mayo Clinic in the U.S.

Feb 21, 2025, 8:15 AM EST - 5 weeks ago

Aditxt Subsidiary Pearsanta Engages Dominari Securities for its Initial Public Offering, to Drive U.S. and Global Commercial Launch of Early Cancer Detection and Diagnosis Targeted for H2 2025

Feb 13, 2025, 8:15 AM EST - 6 weeks ago

Aditxt to Host Fireside Chat on Friday, February 21st at 11:30 AM Eastern Time

Jan 13, 2025, 8:15 AM EST - 2 months ago

Aditxt's Board of Directors Unanimously Approve Positioning Pearsanta for IPO to Support Global Launch of its Early Cancer Detection Platform

Dec 12, 2024, 8:15 AM EST - 3 months ago

Aditxt's Subsidiary Adimune Successfully Completes Preclinical Efficacy and Safety Studies for Its Immune Modulation Therapeutic ADI Platform, Advancing Toward First-in-Human Clinical Trials

Nov 14, 2024, 4:36 PM EST - 4 months ago

Evofem Biosciences Announces Financial Results for the Third Quarter of 2024

Nov 8, 2024, 8:30 AM EST - 5 months ago

Aditxt Provides Update on Equity Line of Credit, ATM Usage, and Outstanding Number of Shares

Nov 7, 2024, 8:30 AM EST - 5 months ago

Aditxt's Target Acquisition Appili Therapeutics Announces Results of Special Meeting of Shareholders

Nov 6, 2024, 8:30 AM EST - 5 months ago

Aditxt Acquisition Target Evofem Biosciences Secures Investor Support Through Voting Agreements for Merger with Aditxt's Subsidiary Adifem

Nov 6, 2024, 8:00 AM EST - 5 months ago

Evofem Secures Investor Support for Proposed Merger through Voting Agreements

Oct 31, 2024, 8:30 AM EDT - 5 months ago

Aditxt's Target Acquisition Appili Therapeutics Announces Alignment with FDA on Development Requirements for ATI-1801 Topical Antiparasitic Product NDA Submission

Oct 30, 2024, 5:00 PM EDT - 5 months ago

Aditxt To Host Virtual Stakeholder Update and Q&A Session on Friday, November 1, 2024, at 11:30 AM Eastern Time

Oct 29, 2024, 8:15 AM EDT - 5 months ago

Sylvia Hermina Joins Aditxt's Board of Directors, Elevating Leadership with Broader Perspectives

Oct 28, 2024, 8:15 AM EDT - 5 months ago

Aditxt Completes Final Equity Investment and Key Milestone Under the Amended and Restated Merger Agreement with Evofem

Oct 21, 2024, 8:15 AM EDT - 5 months ago

Aditxt to Host a Virtual Fireside Chat with Aditxt CEO Amro Albanna and Evofem CEO Saundra Pelletier, Moderated by MD & Media Personality Dr. Drew Pinsky, on October 28, 2024, at 11:30 AM Eastern Time

Oct 10, 2024, 8:15 AM EDT - 6 months ago

Aditxt's Acquisition Target Appili Therapeutics Will Hold a Special Meeting of Shareholders on November 6, 2024, to Vote on the Transaction and Secure Appili's Shareholder Approval

Oct 9, 2024, 10:52 AM EDT - 6 months ago

Aditxt To Host Stakeholder Update and Q&A Session on Friday, October 11, 2024, at 11:30 AM Eastern Daylight Time

Oct 8, 2024, 8:15 AM EDT - 6 months ago

Aditxt Completes Third Parent Equity Investment Under Amended and Restated Merger Agreement With Evofem

Oct 3, 2024, 8:15 AM EDT - 6 months ago

Aditxt Delivers Shareholder Update and 2024 Year-End Plan

Sep 27, 2024, 8:15 AM EDT - 6 months ago

Aditxt, Inc. (NASDAQ: ADTX) Announces 1-for-40 Reverse Stock Split Effective at the Open of Trading on October 2, 2024

Sep 24, 2024, 8:15 AM EDT - 6 months ago

Evofem Biosciences Files Preliminary Proxy for Stockholder Approval of the Acquisition by Aditxt

Sep 20, 2024, 8:15 AM EDT - 6 months ago

Aditxt's Subsidiary Pearsanta to Collaborate with Evofem Biosciences for Targeted U.S. Launch of Endometriosis Diagnostic in Mid-2025

Sep 9, 2024, 8:15 AM EDT - 7 months ago

Aditxt and Evofem Sign Second Amendment to Amended and Restated Merger Agreement, Target Closing of Acquisition in Fourth Quarter of 2024

Sep 4, 2024, 8:15 AM EDT - 7 months ago

Aditxt Subsidiary Pearsanta Submits a Grant Application Seeking to Advance Clinical Trials for Mitomic® Prostate Test, Targeting Early Detection in High-Risk Patients

Aug 29, 2024, 8:15 AM EDT - 7 months ago

Aditxt to Present at the H.C. Wainwright 26th Annual Global Investment Conference September 9th-11th, 2024

Aug 26, 2024, 8:15 AM EDT - 7 months ago

Aditxt's Precision Health Subsidiary, Pearsanta, Appoints Christopher Mitton as President as it Seeks to Complete Clinical Validation Studies for its Mitomic® Endometriosis Test (MET™) and Mitomic® Prostate Test (MPT™)

Aug 21, 2024, 8:15 AM EDT - 8 months ago

Aditxt Announces Third Amendment to Arrangement Agreement with Appili Therapeutics

Aug 20, 2024, 8:17 AM EDT - 8 months ago

Evofem Biosciences Addresses the Impact of GLP-1 Medications on Oral Contraceptive Absorption and Introduces Phexxi as a Non-Oral Solution

Aug 14, 2024, 7:00 AM EDT - 8 months ago

Evofem Biosciences Announces Financial Results for the Second Quarter of 2024

Aug 13, 2024, 8:15 AM EDT - 8 months ago

Aditxt Announces the Successful Passage of all Proposals at Recent Annual Shareholders' Meeting, Setting the Stage for 2024 and 2025 Strategic Plans

Aug 9, 2024, 4:15 PM EDT - 8 months ago

Aditxt Announces Closing of $1.2 Million Registered Direct Offering Priced At-The-Market under Nasdaq Rules

Aug 9, 2024, 8:00 AM EDT - 8 months ago

Aditxt Announces $1.2 Million Registered Direct Offering Priced At-The-Market under Nasdaq Rules

Aug 7, 2024, 8:15 AM EDT - 8 months ago

Aditxt Subsidiary Pearsanta Seeks Clinical Trial Translational Endpoints Research Award for Early Detection of Ovarian Cancer

Jul 25, 2024, 9:00 AM EDT - 8 months ago

Evofem Biosciences to Present at the OTCQB Venture Virtual Investor Conference on August 1st

Jul 25, 2024, 8:30 AM EDT - 8 months ago

Aditxt Signs Second Amendment to the Arrangement Agreement with Appili Therapeutics, Targeting September 30 Closing of the Acquisition

Jul 23, 2024, 8:47 AM EDT - 9 months ago

Evofem Signs Phexxi® License Agreement for Middle East with Pharma 1

Jul 17, 2024, 6:30 AM EDT - 9 months ago

Aditxt and Evofem Amend and Restate Merger Agreement, Targeting September 30 Closing

Jul 15, 2024, 7:20 AM EDT - 9 months ago

Lupin Divests U.S. Commercial Women's Health Specialty Business to Evofem, including SOLOSEC

Jun 27, 2024, 8:36 AM EDT - 9 months ago

Hello Alpha Partners with Evofem to Offer Phexxi® as a Hormone-Free Contraception Solution on its Platform for Women's Healthcare

Jun 11, 2024, 8:36 AM EDT - 10 months ago

Evofem Announces Issuance of New U.S. Patent Covering Phexxi Composition of Matter

May 15, 2024, 6:50 AM EDT - 11 months ago

Evofem Biosciences Announces Financial Results for the First Quarter of 2024

May 3, 2024, 2:14 PM EDT - 11 months ago

CORRECTING and REPLACING Aditxt Announces Pricing of $4.2 Million Private Placement Priced At-The-Market under Nasdaq Rules

May 3, 2024, 9:00 AM EDT - 11 months ago

Aditxt Announces Pricing of $4.2 Million Private Placement Priced At-The-Market under Nasdaq Rules

Apr 2, 2024, 8:30 AM EDT - 1 year ago

Aditxt Signs a Definitive Agreement to Acquire Appili Therapeutics Inc., Developer of a Biodefense Vaccine Funded by the U.S. Department of Defense (DoD)